AstraZeneca China

China
AstraZeneca China is engaged in pharmaceutical development and distribution.

About AstraZeneca China

AstraZeneca China is a Healthcare company based in China. AstraZeneca China is engaged in pharmaceutical development and distribution. It operates on a Direct-to-Consumer (D2C) model. AstraZeneca China offers products and services including Tezspire and Weiliri. Its focus areas include Pharmaceuticals and Biopharmaceuticals.

Company details

AstraZeneca China is involved in the development and distribution of pharmaceutical products. Focus is placed on key disease areas such as cardiovascular, kidney, and metabolic disorders, oncology, respiratory and immunology, digestive health, and rare diseases. Innovative solutions are provided through research and development, commercial strategies, and operational advancements. The company operates within the healthcare sector, contributing to patient care and treatment options across China.

Products & Services of AstraZeneca China

AstraZeneca China offers a comprehensive portfolio of products and services, including Tezspire and Weiliri.

Tezspire
Pharmaceuticals

Tezspire is used for chronic sinusitis treatment.

Weiliri
Pharmaceuticals

Weiliri is offered for rare disease treatment.

Web traffic of AstraZeneca China

Websites that share an audience with AstraZeneca China (astrazeneca.com.cn).

Similar websites

Websites whose visitors overlap most with AstraZeneca China. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
hutch-med.com
100%
13.2K#1,517,293View details
3sbio.com
100%
17.5KView details
qilu-pharma.com
100%
101.1K#245,217View details
gracellbio.com
100%
View details
sanhome.com
100%
#10,286,140View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 8 similar websites and full traffic analytics for AstraZeneca China

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 8 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about AstraZeneca China

AstraZeneca China is headquartered in China.

AstraZeneca China is involved in the development and distribution of pharmaceutical products. Focus is placed on key disease areas such as cardiovascular, kidney, and metabolic disorders, oncology, respiratory and immunology, digestive health, and rare diseases. Innovative solutions are provided through research and development, commercial strategies, and operational advancements. The company operates within the healthcare sector, contributing to patient care and treatment options across China.

AstraZeneca China offers Tezspire and Weiliri.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available